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Background: Accurate mutational analysis, especially epidermal
growth factor receptor (EGFR) mutations, of diagnostic biopsies
from all Asian NSCLC patients is crucial to their clinical manage-
ment, but faces problems. Here, we explore, within usual hospital
constraints, the practicalities of incorporating mutational analysis in
every newly diagnosed case of NSCLC, namely, maximizing tissue
acquisition during the diagnostic procedure and determining the
maximum quantity and quality of DNA sequence data available
from these biopsies.
Methods: Sixty-eight Chinese patients were enrolled. Thirty-five
underwent surgical resections for early-stage tumors. Thirty-three
underwent diagnostic procedures, i.e., needle aspirates under bron-
choscopic or computed tomographic/fluoroscopic guidance, or for-
ceps biopsies via bronchoscopy. Separate samples for research
purposes were obtained from these 33 patients during the diagnostic
procedure. All samples were analyzed for mutations in EGFR exons
18 to 21, p53 exons 4 to 9, and Kras exon 2.
Results: No deaths occurred in this study. Success rates in obtaining
sequence data from surgical samples versus low-volume samples for
EGFR, p53, and Kras were 100% versus 85%, 100% versus 82%,
and 100% versus 85%, respectively. Sequencing nine polymerase
chain reaction products from each low-volume sample resulted in
the exhaustion of all extracted DNA from three samples.
Conclusions: Acquiring a separate low-volume lung biopsy sample
for mutational analysis in lung cancer patients during the diagnostic
procedure is feasible and may be a valuable complement to the usual
diagnostic workflow in future.
Key Words: Non-small cell, Mutational analysis, Diagnosis, Asian,
EGFR, p53, Kras.
(J Thorac Oncol. 2007;2: 387–396)
Lung cancer remains the leading cause of cancer mortality,comprising 17.6% of cancer deaths worldwide, with an
average 5-year survival rate of 9% to 15%.1 The need for
improved strategies in the management of non-small cell lung
cancer (NSCLC) is made more urgent as it constitutes the
majority of cases compared with small cell lung cancer
(SCLC): 85% versus 15%.
As a clinical entity, East Asian nonsmoking women
with lung adenocarcinoma have historically intrigued clini-
cians in Asia. Epidemiological studies have shown lower
smoking rates of 16% to 52% in Chinese female lung cancers
in a scattered geographic distribution, in contrast with 77% to
90% in white women.2 In Chinese-dominated Singapore,
records of lung cancer patients showed that one third were
never smokers, of whom two thirds were female; females
comprised one tenth of smokers/ex-smokers. This suggests
that in Chinese women, the majority of NSCLC cannot be
attributed to smoking.3
Since the discovery of mutations in the tyrosine kinase
(TK) domain of EGFR and their prediction for clinical
response to TK inhibitors (TKIs),4,5 and the correlation with
female gender, nonsmoker status, East Asian ethnicity, and
adenocarcinoma subtype,6–10 there have been efforts focusing
on optimizing the diagnostic process. In so doing, rational
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treatment decisions can be made with maximal impact on
patient benefit and minimal wastage in misallocated re-
sources. This is especially pertinent in Asia where the most
populous nations reside, where the target and resident
populations coincide, and where health care resources vary
regionally.
The majority of NSCLC cases present in the advanced
stages, when surgery is not recommended. For these late-
stage NSCLCs, tissue specimens for analysis are typically
limited to low-volume samples acquired during the diagnostic
procedure, e.g., forceps biopsies via bronchoscopy and needle
aspirates guided by bronchoscopy or computed tomography
(CT)/fluoroscopy. Treatment decisions based on EGFR mu-
tational status rely wholly on the accurate detection of mu-
tations in these tissue samples.
Mutational analysis of diagnostic samples is possible
using paraffin-embedded tissue.11–13 However, results from
DNA sequencing performed on paraffin-embedded materials
should be interpreted with caution and may require indepen-
dent repeat polymerase chain reaction (PCR) for confirma-
tion14 (see Discussion).
Patients with advanced-stage disease do not undergo
surgery, receiving chemotherapy and/or radiotherapy instead.
As standard first-line treatment of late-stage NSCLC is sim-
ilar for all histological subtypes, there had been no clinical
need for subtype specification beyond distinguishing NSCLC
from SCLC in the diagnostic samples. Cell numbers and
available morphological features of the diagnostic biopsy
sample also limit the level of confidence in assigning histo-
logical subtypes. With the advent of EGFR mutations, how-
ever, perhaps the paradigm for lung cancer diagnosis requires
modification, such that treatment decisions regarding TKIs
are not based on phenotype, but on genotype (mutational
analysis), to derive optimal clinical benefit.
This was less of a biological study and more of an
exploration of an alternative approach to mutational analysis
in NSCLC patients, from the perspective of clinical feasibil-
ity. First, we adopted a sequencing strategy and evaluated the
frequency of mutations in EGFR, p53, and Kras in surgical
samples to demonstrate the reliability of our sequencing
technique and validity of the sequence quality. Second, we
showed that within the daily constraints of busy hospitals, we
were able to extract data of similar quality from low-volume
lung biopsy samples obtained in parallel with diagnostic
biopsy samples, bypassing paraffin embedding. We also es-
timated the likely maximum amount of sequencing informa-
tion that can be acquired from these low-volume tissue
samples to set the preliminary stage for possible incorpora-
tion of other gene mutations of clinical significance into the
routine diagnostic process in the future. As the main objective
was to discover the maximal yield of mutations from low-
volume samples, this study did not assess the accuracy of
mutation results by comparing mutations between matched
large-volume (surgical) and low-volume samples from the
same patients.
In summary, this study explored the feasibility of per-
forming mutational analysis on low-volume tissue samples
that are procured separately from those for histological ex-
amination during the diagnostic biopsy procedure in the
context of routine clinical workflow.
PATIENTS AND METHODS
Patients and Sample Collection
Approval for this study was obtained from the institu-
tional review boards of the National University Hospital and
Tan Tock Seng Hospital, Singapore. Samples were obtained
from patients with informed consent. For patients undergoing
surgery, tumor tissue (1 cm3) was obtained from each patient
ex vivo. For patients undergoing nonsurgical diagnostic pro-
cedures, study samples were obtained if the preceding sample
was assessed by a cytologist to contain sufficient cells for
diagnosis. Therefore, study samples were acquired at the
same time as the diagnostic procedure, but were separate
from the diagnostic biopsy samples, thereby not compromis-
ing the usual diagnostic process. Bronchoscopic biopsy sam-
ples were obtained with a 22-gauge Wang cytology needle
(Bard Endoscopic Technologies, Billerica, MA) or forceps
(Olympus America Inc., Center Valley, PA). Percutaneous
needle aspirates were obtained with CT/fluoroscopic guid-
ance using an 18- or 20-gauge Quick-Core needle (Cook Inc.,
Bloomington, IN), or 20-gauge Chiba or Westcott needles
(Medical Device Technologies Inc., Gainesville, FL). As these
were diagnostic procedures, a range of pathologies, both malig-
nant and benign, was included (Table 1). NSCLCs of various
histological subtypes were covered, including adenocarcinoma,
squamous cell carcinoma, and large cell carcinoma. Each aspi-
rate and surgical sample was collected in 80 l and 1 ml of
RNAlater (Ambion, Austin, TX), respectively.
Preparation of Genomic DNA
Genomic DNA was extracted from fresh surgical tis-
sues with Puregene DNA purification kits (Gentra Systems
Inc., Minneapolis, MN), using isopropanol for DNA precip-
itation. To maximize yield for the low-volume samples, DNA
precipitation was achieved with oyster glycogen (Sigma-
Aldrich, St. Louis, MO) added to the last step to a final
concentration of 0.02 g/l and then incubated overnight at
20°C before centrifugation.15 DNA extracted from each
sample was resuspended in 15 l of Tris-ethylenediaminetet-
raacetic acid (pH 7.5) buffer. Quantification of extracted
DNA was performed using the NanoDrop spectrophotometer
(NanoDrop Technologies, Wilmington, DE).
PCR and Purification of PCR Products
Exons 18 to 21 of EGFR, exons 4 to 9 of p53, and exon
2 of Kras were amplified by PCR. Primer sequences (forward
and reverse, respectively) and PCR conditions are as fol-
lows: EGFR exon 18: 5=-CAAATGAGCTGGCAAGTGCCG-
TGTC-3= and 5=-GAGTTTCCCAAACACTCAGTGAAAC-
3=; EGFR exon 19: 5=-GCAATATCAGCCTTAGGTGCGGCT
C-3= and 5=-CATAGAAAGTGAACATTTAGGATGTG-3=;
EGFR exon 20: 5=-CCATGAGTACGTATTTTGAAACTC-3=
and 5=-CATATCCCCATGGCAAACTCTTGC-3=; EGFR exon
21: 5=-CTAACGTTCGCCAGCCATAAGTCC-3= and 5=-GCT
GCGAGCTCACCCAGAATGTCTGG-3=; p53 exon 4: 5=-GTA
AGGACAAGGGTTGGGCT-3= and 5=-ACTGACAGGAAGC
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CAAAGGGT-3=; p53 exons 5-6 5=-CTAGCTCGCTAGTGGGTT
G-3= and 5=-AGGAGAAAGCCCCCCTACTG-3=; p53 exon 7:
5=-TGCTTGCCACAGGTCTCC-3= and 5=- AAGCTCCAGCT
CCAGGTAGG-3=; p53 exons 8 to 9: 5=-TTCCTTACTGCCTC
TTGCTT-3= and 5=-AGAAAACGGCATTTTGAGTG-3=; Kras
exon 2: 5=-TTCTTAAGCGTCGATGGAGG-3= and 5=-ACA
GAGAGTGAACATCATGGAC-3=.
All PCR assays were carried out in 25 l that contained
5 to 100 ng of genomic DNA, 1 unit of platinum Taq DNA
polymerase (Invitrogen, Carlsbad, CA) and 0.3 mM of de-
oxyribonucleoside triphosphate (Bioline Ltd., London, UK).
For DNA samples of concentration greater than 100 ng/l,
100 ng was used as template; for concentration less than 100
ng/l, 1 l was used. Each PCR reaction was subjected to
95°C for 5 minutes before DNA amplification for 35 cycles at
95°C for 30 seconds, and 56°C for 30 seconds, 72°C for 1
minute, with final extension at 72°C for 10 minutes. QiaQuick
PCR purification kits (Qiagen, Hilden, Germany) were used on
PCR products amplified from surgical tissue. To avoid DNA
loss through purification kit columns, exonuclease I (New En-
gland Biolabs, Ipswich, MA) and shrimp alkaline phosphatase
(Promega, Madison, WI) in a 1:10 concentration ratio (ExoSAP)
was added to the PCR products amplified from low-volume
samples to a final volume ratio of 1.1:10, incubated at 37°C for
1 hour and then at 72°C for 15 minutes, according to manufac-
turer’s protocols. This step removes excess primers and deoxyri-
bonucleoside triphosphate.
DNA Sequencing
Purified PCR products were sequenced in forward and
reverse directions using the ABI PRISM BigDye Terminator
Cycle Sequencing Ready Reaction kit (Version 3) and ABI
PRISM 3700 Genetic Analyzer (Applied Biosystems). Chro-
matograms were analyzed by manual review.
Statistical Analysis
The hypergeometric distribution was used to assess the
correlation between gene mutations and patient characteris-
tics (Tables 2 and 3). Fisher’s exact test yielded similar
results. The majority of p values were calculated using the 2
test, which was used in comparisons of patient characteristics
(Table 1) and frequencies of gene mutations (Table 4); the t
test was used to compare ages (Table 1).
RESULTS
Alternative Approach to Obtaining Low-Volume
Lung Tissue For Mutational Analysis is Feasible
There was no mortality associated with the acquisition
of patient samples in this study. The pneumothoraces induced
TABLE 1. Characteristics of Patients and Tumors
Low-Volume Samples
Surgical Samples Total Excluding ‘Others’
No. of patients 35 33 24
Age, yr p  0.023a
Median 64 70 70
Range 39–81 33–83 52–83
Gender p  0.67
Male 26 (74%) 25 (76%) 19 (79%)
Female 9 (26%) 8 (24%) 5 (21%)
Smoking status p  0.006
Never smokers 12 (34%) 4 (12%) 1 (4%)
Smokers and ex-smokers 23 (66%) 29 (88%) 23 (96%)
No. of samples 35 34 24
Histology/cytology p  0.0004
Adenocarcinoma 16 (46%) 6 (17%) 6 (25%), p  0.1
Squamous cell carcinoma 15 (43%) 8 (23%) 8 (33%), p  0.46
Large cell carcinoma 1 (3%) 5 (15%) 5 (21%), p  0.02
Adenosquamous carcinoma 1 (3%) 0 0, p  0.4
Undifferentiated 2 (6%) 1 (3%) 1 (4%), p  0.79
NSCLC, unspecified 0 4 (12%) 4 (17%), p  0.01
Others
Malignant, non-NSCLC primary 0 3 (9%)
Malignant, metastases 0 2 (6%)
Nonmalignant 0 5 (15%)
(2 samples were from
the same patient)
For comparisons in histology/cytology, the p value for overall distribution of subtypes is shown at the top; individual subtype
comparisons are also given. The two groups being compared are surgical samples and low-volume samples, excluding others.
a Student’s t test was used to compare the distribution of age between both groups.
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iatrogenically were small and did not require draining, oc-
curring at a rate of 14% to 15%, comparable with previous
internal audit data of the participating institutions. There was
no other procedure-related morbidity, e.g., uncontrollable
hemorrhage, hypoxia.
The time taken to acquire a separate research sample in
the same sitting as the diagnostic procedure did not significantly
affect the work flow of the interventional radiologists or respi-
ratory physicians. Their usual clinical load was adequately
managed within the usual working hours. The samples for this
study circumvented the usual flow to the Pathology Department
and were directly processed for mutational analysis.
Patient and Tissue Sample Characteristics
A total of 68 ethnic Chinese patients were included in
this study; 35 patients provided 35 surgical samples and 33
patients provided 34 low-volume samples (one patient pro-
vided two samples).
All surgical samples had confirmed histological diag-
noses of various NSCLC subtypes (i.e., adenocarcinoma,
squamous cell carcinoma). The 34 low-volume samples were
not microscopically examined, but their corresponding diag-
nostic biopsy reports showed that five were nonmalignant
with inflammatory and/or necrotic changes, two were metas-
tases of other adenocarcinoma primaries (breast, salivary
gland), one was a mesothelioma, one was a sarcoma, and one
was a malignancy of neuroendocrine origin. Of the remaining
24 low-volume samples, all were biopsies of lung primaries,
and their corresponding diagnostic biopsy samples were cy-
tologically assessed as NSCLC, although four could not be
further subtyped as adenocarcinoma, squamous cell carci-
noma, etc., owing to the limitations of cell numbers and
TABLE 2. Mutations Detected in Surgical Samples
Sample
Identity Gender
Age,
yr Histology
Smoking
Status
Mutations
EGFR p53 Kras
CT3 F 41 Adenocarcinoma NS — — —
CT7 M 79 Squamous cell carcinoma S — — —
CT9 M 81 Adenocarcinoma S — — —
CT11 M 61 Large cell carcinoma S — — —
CT13 F 57 Adenocarcinoma NS Exon 18:E709A (GA)G719S (AG) — —
CT15 M 44 Squamous cell carcinoma S — — —
CT17 M 57 Adenocarcinoma S — — —
CT19 M 73 Squamous cell carcinoma NS Exon 21:L858R (GT) — —
CT21 M 62 Squamous cell carcinoma S — — —
CT23 M 69 Squamous cell carcinoma S — — —
CT25 M 47 Adenocarcinoma S — — —
CT27 F 72 Adenocarcinoma NS — — —
CT29 M 69 Squamous cell carcinoma S — — —
CT31 F 52 Squamous cell carcinoma NS Exon 21:L833V (GT)L858R (GT) — —
CT33 M 72 Adenocarcinoma S Exon 20:Q787Q (GA) — —
CT35 F 75 Adenocarcinoma NS Exon 18:G719S (GA) — —
CT37 M 71 Adenocarcinoma S — Exon7:S241A(TG) —
CT39 M 74 Squamous cell carcinoma S — — Exon2:G12D(GA)
CT41 M 66 Squamous cell carcinoma S — — —
CT43 F 76 Adenocarcinoma NS — — —
CT45 M 78 Squamous cell carcinoma S — — —
CT53 M 42 Adenocarcinoma S — — —
CT59 M 53 Undifferentiated S — — —
CT63 M 48 Squamous cell carcinoma NS — — —
CT65 M 61 Adenocarcinoma S — — —
CT71 M 64 Squamous cell carcinoma S — — —
CT73 M 64 Squamous cell carcinoma S — — —
CT75 F 65 Adenocarcinoma NS Exon 21:L858R (GT) — —
CT77 M 69 Squamous cell carcinoma S — — —
CT81 F 39 Adenocarcinoma NS Econ 21:L858R (GT) — —
CT105 M 67 Adenocarcinoma S — — —
S21 M 63 Undifferentiated S — — —
S25 M 73 Adenosquamous NS Exon 21:L858R (GT) — —
S27 M 58 Squamous cell carcinoma S — Exon5:R158L(GT) —
S29 F 63 Adenocarcinoma NS Exon 21:L858R (GT) — —
NS, never smoker; S, smoker or ex-smoker.
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TABLE 3. Low-Volume Samples: Mutations Detected, Biopsy Procedures, DNA Yield
Sample
Identity Gender
Age,
yr Cytology
Smoking
Status
Mutations
Biopsy
Procedure
DNA
Yield (ng)EGFR p53 Kras
G1 M 65 Non-small cell lung
cancer
S Exon 21: L833V
(GT)L858R
(GT)
— — Needle
aspirate
76
G2 M 78 Adenocarcinoma S — — — Core biopsy 2941
G3 M 58 Squamous cell carcinoma S — Exon 5:R158L
(GT)
— Core biopsy 2904
G4 M 73 Squamous cell carcinoma S — — — Needle
aspirate
287
G6 M 84 Squamous cell carcinoma S Exon 21:L833V
(GT)L858R
(GT)
— — Needle
aspirate
67
G7 M 54 Squamous cell carcinoma S — Exon 7:M237I
(GA)
— Needle
aspirate
403
G9 M 63 Squamous cell carcinoma S Exon 21:L833V
(GT)L858R
(GT)
— — Needle
aspirate
106
G10 M 70 Large cell carcinoma S — — — Needle
aspirate
198
G21 F 33 Adenocarcinoma
(metastasis from
breast)
NS — — — Core biopsy 1773
G22 M 75 Non-small cell lung
cancer
S Exon 21:L833V
(GT)L858R
(GT)
— — Core biopsy 3000
G23 F 58 Adenocarcinoma NS — — — Needle
aspirate
226
G24 M 68 Non-small cell lung
cancer
S — — — Core biopsy 3214
G25 M 33 Nonmalignant,
necroinflammatory
NS — — — Core biopsy 1864
G26 M 63 Undifferentiated S — — — Needle
aspirate
144
G27 M 75 Mesothelioma S — — — Needle
aspirate
657
G28 M 74 Adenocarcinoma S — Exon 5:A138V
(GT)
— Forceps 256
G29 M 59 Large cell carcinoma S — — — Needle
aspirate
196
G32 F 83 Squamous cell carcinoma S — — — Forceps 2378
G36 M 73 Squamous cell carcinoma S Exon 21:L833V
(GT)L858R
(GT)
— — Needle
aspirate
76
G37 M 70 Adenocarcinoma S Exon 21:L833V
(GT)
— — Needle
aspirate
98
G38 M 59 Large cell carcinoma S — Exon
6:Q192stop
(CT)
— Needle
aspirate
410
G39 M 52 Adenocarcinoma S — — — Core biopsy 1726
G40 M 60 Adenocarcinoma S — Exon
7:Y236stop
(GA)
— Needle
aspirate
321
G41 M 81 Nonmalignant S — — — Forceps 1779
G46 M 81 Nonmalignant S — — — Forceps 812
G67 F 82 Adenocarcinoma
(metastasis from
salivary gland)
S — — — Core biopsy 5993
H1 M 65 Nonmalignant, necrotic S — — — Needle
aspirate
1378
(Continued)
Journal of Thoracic Oncology • Volume 2, Number 5, May 2007 Use of Low-Volume Lung Biopsies
Copyright © 2007 by the International Association for the Study of Lung Cancer 391
available morphological features. All 24 patients were in the
advanced stage of disease; therefore, surgery was not part of
their clinical management. Table 1 lists the patient charac-
teristics and tumor histology/cytology. The distribution of
smoking status and histological subtypes are significantly
different (see Discussion).
High Success Rate in Obtaining Sequence Data
from Low-Volume Lung Tissue
Genomic DNA was successfully extracted from all
surgical and low-volume samples. For the low-volume sam-
ples, the range of DNA quantities extracted varied between
67 and 6900 ng (median, 812 ng; see Table 3). Typical
values for the Quick-Core needle biopsies and forceps
biopsies were greater than 1000 ng, whereas those for the
Wang, Chiba, and Westcott needle biopsies were less than
300 ng. The size and location of the lesions helped deter-
mine which needles were used: the larger and more pe-
ripheral the lesion, the more likely the Quick-Core needle
was used. The choice of needle was left to the operator’s
discretion.
We were able to obtain sequence data from all the
surgical samples. The success rates of obtaining sequence
data from the low-volume samples for EGFR, p53, and Kras
were 85%, 82%, and 85%, respectively. The EGFR (exons
18, 19, 20, 21) and p53 (exons 4, 5  6, 7, 8  9) analysis
included sequencing four PCR products each, whereas only
one PCR product was sequenced for Kras (exon 2). For
EGFR and p53, success was scored as being able to obtain
sequence data from at least three of four PCR products (Table
2). Additionally, sequence data from both EGFR exons 19
and 21 (which contained the most common mutations) had to
be obtained to be considered a success (Table 5).
Figure 1 illustrates the quality of the mutation detec-
tion. All PCR products were sequenced bidirectionally, which
served to confirm mutations.
Comparing Detection Rates of EGFR, p53, and
Kras Mutations in Low-Volume Lung Tissue
Samples and Surgically Resected Lung Tissue
Tables 2 and 3 illustrate the EGFR and p53 mutations
detected in both surgical and low-volume lung samples.
TABLE 4. Mutation Frequencies
Surgical Group Low-Volume Group
EGFR 9/35 (26%) 6/24 (25%), p  0.95
p53 2/35 (6%) 6/24 (25%), p  0.034
Kras 1/35 (3%) 0, p  0.4
EGFR mutations
Shigematsu et al.8
Females 55% (110) 67% (6/9), p  0.48 0% (0/5), p  0.2
Males 19% (251) 12% (3/26), p  0.33 32% (6/19), p  0.017
Never smokers 56% (135) 73% (8/11), p  0.29 0% (0/1), p  0.13
Smokers or ex-smokers 14% (226) 4% (1/24), p  0.17 26% (6/23), p  0.26
Adenocarcinoma 48% (214) 44% (7/16), p  0.74 17% (1/6), p  0.13
Nonadenocarcinoma 3% (147) 11% (2/19), p  0.086 21% (3/14), p  0.001; ‘unspecified
NSCLC’ is disregarded
Comparing EGFR, p53, and Kras mutations between surgical and low-volume lung samples. Comparing EGFR mutations between Asian
men and women, smokers/ex-smokers and never smokers, adenocarcinoma and nonadenocarcinoma histology, with Shigematsu et al.8 as
reference. NSCLC, non-small cell lung cancer.
TABLE 3. (Continued)
Sample
Identity Gender
Age,
yr Cytology
Smoking
Status
Mutations
Biopsy
Procedure
DNA
Yield (ng)EGFR p53 Kras
H16 M 73 Carcinoma,
neuroendocrine
S — — Exon 2:K5N
(AT)
Needle
aspirate
2496
H18 F 58 Nonmalignant, necrotic NS — — — Core biopsy 2856
T23 M 81 Large cell carcinoma S — Exon 8:R273L
(TG)
— Needle
aspirate
2031
T24 F 80 Large cell carcinoma S — — — Needle
aspirate
707
T25 M 75 Sarcoma S — — — Core biopsy 6901
T26 F 81 Squamous cell carcinoma S — — — Forceps 1692
T27 M 83 Non-small cell lung
cancer
S — — — Forceps 3523
G41 and G46 were obtained from the same patient. NS, never smoker; S, smoker or ex-smoker.
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EGFR mutations are positively correlated with female gender
(p  0.003), nonsmoking status (p  1.6e-04) and adenocar-
cinoma subtype (p  0.03) in the surgical group. This
correlation was, however, not observed in the low-volume
samples. All EGFR mutations detected in the low-volume
group occurred in male smokers (see Discussion). Similarly,
all p53 mutations occurred in male smokers (see Discussion).
Table 4 compares the frequency of mutations detected
in the surgical specimens and low-volume samples. For EGFR,
the mutation rates were not significantly different (p  0.95)
at 26% and 25% for surgical and low-volume samples,
respectively. No novel mutations were detected. The most
frequently detected were the commonly reported L858R mis-
sense mutation, occurring in 11 of 15 samples with EGFR
mutations, followed by the L833V mutation, occurring in
seven cases. In fact, L833V was present in combination with
L858R in six cases (one surgical, five low-volume samples).
For p53 mutations, the detection rates were significantly differ-
ent (p  0.034) at 6% and 25% for surgical and low-volume
samples, respectively. Only one of 35 (3%) surgically resected
tumors had a Kras mutation (G12D, GA), and one Kras
mutation (K5N, AT) was detected in a low-volume sample
that corresponded to a malignancy of neuroendocrine origin
(categorized as malignant, non-NSCLC primary in Table 1).
None of the mutations detected coexisted with mutations of
another gene.
Apart from the single Kras mutation found in the
malignancy of neuroendocrine origin, there were no other
mutations found in the remaining nine low-volume samples
that were nonmalignant or from non-NSCLC primary malig-
nancies and metastases.
DISCUSSION
This report examines an alternative approach to muta-
tional analysis of low-volume lung tissue samples, with a view
to clinical application. It also offers further insight into the
mutational status of NSCLC in an ethnic Chinese population.
The dilemma of obtaining histological validation and
maximal sequence information from a low-volume sample is
not easily resolved. It would be ideal for every sample to be
visually examined before the relevant cells are selected (e.g.,
using laser capture microdissection) for sequencing. Less
than ideal would be to split the sample contents for histolog-
ical validation and direct sequencing. Both scenarios are
subject to acquiring enough cells per sample. Increasing the
cell yield per patient can be achieved by additional sampling.
The issue of sampling error then arises where the site of
sampling may not be duplicated, although this may be min-
imized (see below). Nonetheless, it may be reasonable to
regard directly sequencing a separate sample as being equiv-
alent to directly sequencing one part of a sample that has been
split (one part for direct sequencing, one part for histological
validation), in the sense that in both cases, the cells for
sequencing were not first directly validated histologically. On
this basis, we designed the study such that a diagnostic
sample is obtained for histological validation, and a research
sample is acquired for direct sequencing.
With each additional sample acquisition, the impact on
clinical safety and work flow also needs to be considered.
Unlike other sites where sample acquisition poses low clini-
cal risk, e.g., breast, skin, obtaining samples of lung tissue
involves greater morbidity. Clinical risk notwithstanding, as
sequencing expertise is getting more widely available and
increasingly affordable, it seemed sensible to explore its
TABLE 5. Success in Obtaining Sequence Data from PCR Products Amplified from Low-Volume Lung Samples
EGFR p53 Kras
n of 4 PCR Products No. of Samples n of 4 PCR Products No. of Samples n of 1 PCR Product No. of Samples
4 29 4 14 1 29
3 2 (exon 19 sequence not obtained) 3 14 0 5
2 0 2 1
1 0 1 4
0 3 0 1
Success rate
29/34  85% 28/34  82% 29/34  85%
PCR, polymerase chain reaction.
FIGURE 1. Quality of sequence data from low-volume sam-
ples. A and B: EGFR L833V mutation, in forward and reverse
directions. C and D: EGFR L858R mutation, in forward and
reverse directions.
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inclusion in hospital work flows, especially in Asia where the
expected clinical impact is great. On balance, we considered
it a worthwhile effort to obtain more cells per patient for
direct sequencing, not only to increase the chances of cap-
turing sequence data from as many patients as possible, but
also to see whether the reliance on paraffin-embedded cells
could be lessened. Our emphasis was on striking a balance
between the practical feasibility within usual hospital con-
straints (e.g., financial, clinical safety, hospital work flow,
timeliness of results), and the delineation of the limits of
DNA sequence information obtainable. We would not lay
claim that we have obtained results comparable with the ideal
situation outlined earlier. Instead, this is an exploration of
alternative measures to circumvent the inherent limitations
and difficulties in analyzing low-volume samples.
Essentially, the existing issues in current practice that
impede the broad application of mutational analysis to all
newly diagnosed lung cancer patients are as follows: (1)
insufficient cells in the diagnostic samples; (2) paraffin em-
bedding may cause deamination, masking true mutational
status; (3) limited availability of precision equipment for cell
selection, e.g., laser capture microdissection.
Not every case has sufficient cells left over from the
diagnostic biopsy with which to construct paraffin-embedded
cell blocks. In the Shih et al.16 retrospective study of lung
cancer patients receiving gefitinib treatment, in 75 of 139
(54%) patients, there were no paraffin-embedded cells from
their diagnostic biopsy samples, and thus they were excluded
from analysis. Scraping cells off the diagnostic glass slide is
an alternative that we have not evaluated. However, the
physical manipulation and staining/destaining processes may
be expected to compromise DNA quality and quantity.
Analyzing mutations in paraffin-embedded cells has
been criticized, owing to the likely deamination of cytosine/
adenine residues.14 This change is reflected in subsequent
PCR amplifications, giving rise to inaccurate mutation re-
sults. Taking a separate sample for immediate DNA sequenc-
ing offers an alternative route to acquiring similar informa-
tion from paraffin-embedded tissue. Additional sampling also
ensures increased cell numbers, but introduces another fore-
seeable limitation, namely, the possible nonconcordance of both
samples due to the lack of morphological confirmation of the
additional sample. Attempting to biopsy twice at the same site
may minimize this, although this is dependent on the skill of the
operators and the size and location of the lesion. For core biopsy
samples, they are obtained coaxially through a sheath. By
keeping the sheath in the same position, the likelihood of being
able to obtain a biopsy sample from the same site again is
increased. Bronchoscopists are guided visually by the preceding
puncture site.
Laser capture microdissection can enrich for tumor
cells, increasing the sensitivity of analysis. However, this
equipment is not widely available and requires additional
processing time. Constructing paraffin-embedded cell blocks
is also time-consuming. Recently developed methods of de-
tecting mutations, e.g., denaturing high-performance liquid
chromatography,17,18 may be used as screening measures
before sequencing, thereby increasing overall efficiency of
analysis. Again, availability of instruments is limited.
For any new measure to be successfully incorporated
into clinical practice requires consideration of the degree of
clinical benefit that can be promptly derived and the ease of
integration into hospital workflows. Obtaining an additional
sample at diagnosis appears to satisfy both criteria.
The ongoing IRESSA pan-Asian study trial (AstraZen-
eca) directly compares first-line gefitinib with standard intra-
venous platinum-based chemotherapy for advanced NSCLC
in an Asian population. If the outcome clarifies and supports
the role of EGFR mutational analysis at diagnosis, then
devising hospital workflows to provide timely mutation re-
sults to the clinic will benefit patients.
By investigating the presence or absence of EGFR, p53,
and Kras mutations, we had simultaneously explored the
limits of low-volume samples for mutational analysis by
sequencing. We conclude that the majority of low-volume
samples had sufficient DNA to accommodate the sequencing
of nine PCR products, even allowing for failed attempts.
There were three samples where the extracted DNA was
entirely used for this study. This may be taken into consid-
eration in the future, when synthesizing a panel of the most
clinically useful mutations to be analyzed in the diagnosis of
lung cancer.
The lack of correlation between EGFR mutations and
female gender, histology, and smoking status in the low-
volume samples may be related to the different distributions
of smokers and histological subtypes between the surgical
and low-volume sample groups (Table 1). Whether this was
affected by the patients’ perception of risk and consent giving
is unclear. Although all patients who consented to surgery
also consented to providing research samples (no risk), only
40% of patients approached for low-volume samples gave
consent (risk of morbidity).
Table 4 compares the rates of Shigematsu et al.8 of
EGFR mutations in surgical tumors from East Asians with
our corresponding rates in the surgical and low-volume sam-
ple groups. Although there is good concordance of results
between Shigematsu et al. and our surgical group, validating
the quality of our sequence analysis, there are apparent
differences as compared with the low-volume sample group.
The greater proportion of males, smokers, and nonadenocar-
cinomas with EGFR mutations in the low-volume sample
group may represent a true phenomenon or may be partly
attributed to a hidden selection bias from the consent-giving
process.
We compared results from our low-volume sample
group with those reported by Shih et al.16 They had examined
EGFR mutations in paraffin-embedded cells from low-vol-
ume lung samples, which occurred in 49% of adenocarcino-
mas, in contrast with our result of 17%. However, unlike our
unselected series, their retrospective series was selected for
NSCLC and comprised mainly adenocarcinomas (92%). Our
lower-than-expected figure could also be attributed to the
exclusion from our calculation of NSCLC cases that could
not be further subtyped but harbored EGFR mutations. If we
had assumed they were adenocarcinomas, the proportion
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would be 50%. Although we did not report exon 19 deletions
here, we found them in subsequent analysis of tumors not
included in this study, using the same sequencing method.
Nevertheless, the observed discrepancies need not de-
tract from the main focus of this study, i.e., the feasibility of
acquiring additional low-volume lung samples for mutational
analysis. We note that two patients with EGFR mutations
from the low-volume sample group had cytological reports of
NSCLC without further subtyping. According to phenotype,
the likelihood of their being offered TKI would have been
diminished, as they are male smokers. In so doing, the
potential clinical benefit for these two patients would not
have been realized.
Both p53 and Kras mutations have been implicated in
smokers with NSCLC.8,19–21 With the greater preponder-
ance of smokers in the low-volume sample group than the
surgical group, we would expect a higher frequency of p53
and Kras mutations in the former than the latter. This is the
case for p53, where the frequency of mutations is signif-
icantly higher (25% versus 6%). However, there were no
Kras mutations in the low-volume sample group, and only
3% of the surgical samples had a Kras mutation. This
could be partly due to the smaller proportion of adenocar-
cinomas (25%) in the low-volume group compared with
the surgical group (46%), as Kras mutations are positively
correlated with adenocarcinomas.8,22,23
Stage of disease is an important determinant of prog-
nosis and treatment decisions in NSCLC. The role of p53 as
a prognostic factor in lung cancer has been studied in relation
to disease stage and included in several meta-analyses.24–26
We could hypothesize that the increased frequency of p53
mutations in the low-volume sample group, as compared with
the surgical group, is a reflection of the different stages of
disease represented by both groups. Whereas the surgical
group consisted of patients with early-stage disease (stages
I/II), the low-volume group comprised patients with late-
stage disease (stages III/IV). In this context, the difference in
disease stage between the surgical group and the low-volume
group has allowed a preliminary comparison of mutation
patterns between early- and late-stage disease.
There are several other aspects to consider regarding
the limitations of our study. The expected low cell numbers
per low-volume sample was a compelling factor in our
decision to sacrifice histological confirmation of the low-
volume research samples and use the histology reports of the
corresponding diagnostic biopsies as proxy to achieve the
overall objective of gaining the maximal amount of sequenc-
ing information from the maximal number of exons. This led
to the preclusion of mutation confirmation by separate inde-
pendent PCR, as recommended by Marchetti et al.,14 in
evaluating mutations from paraffin-embedded cells, although
the PCR products in this study were all sequenced bidirec-
tionally (Figure 1). The higher-than-expected frequency of
L833V mutation occurring synchronously with the L858R
mutation in our series could not be further confirmed with
separate independent PCR as the DNA was interrogated for
mutations in other exons. The L833V mutation has only been
previously reported by Huang et al.7 and occurred indepen-
dent of the L858R mutation. This limitation has highlighted
the importance of prioritization of exons to sequence and
mutation confirmation.
In conclusion, acquiring an additional sample of lung
tissue during the diagnostic procedure for lung cancer pa-
tients is feasible. This is easily incorporated into clinical
practice and does not pose unacceptable risks to patients.
Although there are technical limitations, it allows for muta-
tional analysis in more patients, influencing treatment deci-
sions in a timely fashion, thereby serving as a possible useful
complement to the usual diagnostic work flow in hospitals.
With ongoing advances in technology, specifically issues on
its availability and affordability, this step may be further
refined in future.
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